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Biochemical (prostate specific antigen [PSA]-only) relapse is currently
the most common form of advanced prostate cancer. Every third patient
will experience rising PSA levels after prostatectomy [1] or radiotherapy
[2]. Approximately 40% of the patients who receive definitive treatment
for prostate cancer with an intention to cure show a recurrence, and of
these cases more than 90% will progress to bone metastasis [2]. Hormonal
therapy and chemotherapy are well-established treatment options that pro-
long survival in combination with radiotherapy or operation [3]. However,
timing the initiation of these therapies is still a matter of debate and their
roles as adjuvant therapies to prevent metastasis are not well defined.
Bisphosphonates were recently incorporated into the concept of mul-
timodality therapy for the treatment of prostate cancer because they delay
the time and frequency of fractures due to bone metastasis. Moreover,
bisphosphonates may have a role in the prevention of bone metastasis due
to their well-known in vitroeffects on cancer cells [4,5]. We report here
on the effects of intravenous (IV) bisphosphonate on the time to develop
bone metastasis in a high-risk group of patients who were subjected to
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Purpose
High-risk prostate cancer patients undergoing treatment often experience biochemical recur-
rence. The use of bisphosphonates as an adjuvant treatment delays skeletal events, yet whether
or not bisphosphonates also delay metastastic development remains to be determined.
Materials and Methods
A total of 140 high-risk prostate cancer patients who were undergoing definitive treatment and
who had clinically organ-confined disease and who suffered from biochemical recurrence were
administered intravenous (IV) clodronate. The patients were treated with a radical retropubic
prostatectomy (RP) or curative radiotherapy (RTx). Upon androgen deprivation therapy initiation,
tri-monthly IV clodronate was added to the treatment to prevent bone demineralization. Twenty-
six out of 60 operated cases and 45 out of 80 irradiated cases received bisphosphonate. The length
of time until the first bone metastasis was recorded and analyzed.
Results
No statistical difference was found for the type of primary treatment (RP or RTx) on the time to
the first bone metastasis (95% confidence interval [CI], 0.40 to 2.43; p=0.98). However, there was
a clear advantage favoring the group that received bisphosphonate (p＜0.001). The addition of
bisphosphonate delayed the appearance of the first bone metastasis by seven-fold (95% CI, 3.1
to 15.4; p＜0.001).
Conclusion
Treatment with tri-monthly IV clodronate delayed the time to the first bone metastasis in high-risk
prostate cancer patients who were experiencing an increase in the prostate specific antigen
level after definitive treatment.
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definitive therapy with the intention to cure. 
M ater ials  and  Methods
A total of 140 patients with high-risk prostate cancer [6] and clinically
organ-confined disease were enrolled in a prospective sequential open-
label study. The patients were recruited from a larger pool where some of
them were prospectively studied for their bone mineral density. High-risk
patients were identified based on the following: a patient with a Gleason
score of 8, 9 or 10, or a patient with a Gleason score of 7 (4+3 or 3+4) and
an additional finding of minor components with a Gleason score of 5 on
the sample biopsy (for those submitted to radiotherapy) or at a pathological
exam [7]. This study was approved by the local ethics committee for re-
search.
The selected patients with no prior neoadjuvant treatment were treated
with either consensual radical retropubic prostatectomy (RP) or external
beam radiotherapy (RTx) with the intention to cure.
Recurrence of the disease was defined as three consecutive increases
in serum PSA levels.
After the verified recurrence of increased PSA levels, all the patients
received androgen deprivation therapy (ADT) with an luteinizing-hor-
mone-releasing hormone-analog to achieve a testosterone level ＜50
ng/mL, which was regularly checked.
Each branch of definitive therapy, either radiotherapy or surgical, was
administered at the same time the ADT was started, with or without clo-
dronate infusions.
Routine densitometry and bone scans were routinely done every 6
months regardless of the presence of pain. Site-specific exams were re-
quested when pain appeared.
Metastatic confirmation was performed by two single-blinded radiol-
ogists using serial bone scintigraphy and image progression. When un-
certainty persisted, regional magnetic resonance imagings and/or bone
biopsies were done for confirmation.
The patients were analyzed according to the primary therapy that they
received: radical RP or conformal RTx. External beam radiotherapy treat-
ment was planned at a conformational station to deliver 6,800 cGy. 
Inside each modality arm of primary treatment (we intended to treat
70 cases in each arm), all the patients were randomly assigned to receive
adjuvant bisphosphonate infusions every three months after the detection
of biochemical recurrence. Other patients did not receive infusions and
they had no clinical variables conflicting with their treatment choice. 
Twenty-six out of 60 operated patients received bisphosphonate,
whereas 45 out of 80 irradiated patients received the same treatment reg-
imen: 1,500 mg of clodronate every three months in two hour infusions.
The median follow up in the RP group was 78 months (range, 50 to 124
months), whereas in the irradiated group, the patients were followed for
a median time of 67 months (range, 50 to 119 months). The time to the
Values are presented as number (%). RP, radical retro-pubic prostatectomy; RTx, radiotherapy; PSA, prostate specific antigen; Gleason, score de
Gleason.
With bisphosphonates  Without bisphosphonates 
RP                   RTx RP          RTx                       
No. of patients 26 45 34 35
Age at diagnosis 62.3 64.3 61.7 66.8
Clinical stage
T1b 1 (3.8) 2 (4.4) 2 (5.6) 1 (2.9)
T1c 4 (15.2) 6 (13.2) 5 (14) 4 (11.4)
T2a 11 (41.8) 14 (31.1) 11 (30.8) 11 (31.4)
T2b 9 (34.2) 8 (17.6) 15 (42) 9 (25.6)
T2c 1 (3.8) 15 (33) 1 (2.8) 1 (2.9)
PSA at diagnosis 9.1 11.2 8.7 12.1
No. of positive margins 11 (42.3) - 15 (44.1) -
No extracapsular extension 10 (38) - 15 (44.1) -
No seminal vesicle invasion 5 (11) - 6 (16.8) -
No positive lymph nodes 2 (6.8) - 3 (8.4) -
Gleason 7 9 (34.6) 30 (66.6) 20 (58.8) 25 (71.4)
Gleason 3+4+5 5 19 14 19
Gleason 4+3+5 4 11 66
Gleason 4+4 8 (30.7) 9 (20) 7 (20.5) 8 (22.8)
Gleason 5+4 or 4+5 9 (34.6) 6 (13.3) 7 (20.5) 1 (4)
Gleason 5+5 0 1 (2.2) 0 1 (4)
Table 1. Pretreatment variables and cancer characteristics of the treated groups of high-risk cancer patientsPaulo Rodrigues, Adjuvant Effect of Bisphosphonates on Bone Metastasis
VOLUME 43  NUMBER 4  DECEMBER  2011   233
first bone metastasis was recorded and statistically analyzed using the Ka-
plan-Meier curve and log-rank statistical tests to differentiate the time to
the first bone metastasis for each group with each type of primary treat-
ment and by differentiating those with or without bisphosphonates. Cox’s
regression analysis was used to determine whether or not the primary type
of treatment and usage of bisphosphonate might delay the time until the
first bone metastasis. p-values＜5% were considered statistically signifi-
cant.
R esults
Although this study was not double-blinded, the four groups were well-
balanced with regards to age, the clinical stage, positive margins, seminal
vesicle invasion, lymph nodes involvement, and the histological pattern
in each comparison depicted in Table 1.
Only one patient demonstrated chills on the third infusion, which was
a minor adverse effect that did not require clodronate treatment to stop it.
One patient in the RP treatment group and three in the RTx treatment
group with bisphosphonate infusions presented pain as the initial sign of
bone metastasis before the regular exam identified the metastasis. Pain
was the first manifestation of bone metastasis for patients who did not re-
ceive bisphosphonate.
For this specific subset of high-risk prostate cancer patients, there was
no statistical difference concerning the type of primary treatment for
prostate cancer and the time to the first bone metastasis (95% confidence
interval [CI], 0.40 to 2.43; p=0.98).
The primary treatment modality (RP or RTx) did not significantly affect
the time to the first bone metastasis. However, the addition of bisphos-
phonate significantly affected this measure. There was a clear advantage
for the group that received bisphosphonate compared to those who did
not receive it (p＜0.001) regardless of the type of primary treatment 
(p＜0.001).
During long-term follow-up, the regular use of bisphosphonate delayed
the appearance of the first bone metastasis seven-fold over the lag time for
those patients who did not receive bisphosphonate, despite the type of the
primary treatment (95% CI,  3.1 to 15.4; p＜0.001), as depicted in Fig. 1.
Only one case progressed to death during the analyzed follow-up time.
Discussion
Prostate and breast cancer are well-known cancers that regularly metas-
tasize to bone. 
Skeletal complications of bone metastases increase the risk of death
and undermine the patients’ functional independence and quality of life
[8]. Bisphosphonates have been used for more than fifteen years to im-
prove the outcome of patients with bone metastasis from solid tumors.
Emerging evidence indicates that the potential benefits of bisphospho-
nate therapy extend beyond the treatment of metastatic bone lesions.
The benefits of bisphosphonates as an adjuvant therapy to treat the pro-
gression of prostate cancer showed clinical benefits such as the delay of
the first skeletal event [9], pain control [10], and delay or reversal of bone
demineralization due to the anti-hormonal agents that are regularly used
for treating advanced stages of prostate cancer [11].
The use of bisphosphonates effectively inhibits osteoclast-mediated
bone resorption, and so this provides the rationale for their use for skeletal
protection in the endless bone remodeling process.
Preliminary preclinical studies with zoledronic acid and other bispho-
sphonates have demonstrated that they have in vitro anti-tumor properties,
and their effects extend beyond the treatment of bone metastasis [12,13],
and bisphosphonates even delay the development of metastasis. This pre-
viously unrecognized, but fortuitous anti-angiogenic [14], anti-adherence,
and anti-invasion adjuvant effects on cancer cells [15] may be the key to
preventing the formation of metastatic niches in the bone.
Animal studies have shown that bisphosphonates can reduce the rate
of developing bone metastases (for example, in Walker 256 carcinoma),
but there is little evidence of an effect at non-osseous sites. The hypothesis
that the growth of sub-clinical osseous metastases is augmented by prod-
ucts of bone resorption (“the vicious cycle”) and that it may be diminished
by a local reduction of these substances with bisphosphonates, has led to
clinical trials involving patients with no clinical evidence of bone metas-
tases, yet  definitive results have not yet been reported.
In breast cancer treatment, the use of oral clodronate was shown to
delay the occurrence of bone metastases in patients subjected to radical
Fig. 1. Number of participants by health insurance type and age from
the National Cancer Screening Program, 2008. RP, radical retro-pubic
prostatectomy; RTx, radiotherapy.Cancer Res Treat. 2011;43(4):231-235
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mastectomy, except for those patients with cancer cells already in the bone
marrow, which is a well-known high-risk factor for the development of
distant metastases [16].
A significant number of patients with organ-confined prostate cancer
have been identified to be at high-risk of treatment failure (exceeding
50%) at three years. This figure includes those who patients who presented
with an initially increased PSA level greater than 20 ﾵg/L, a Gleason score
greater than 7, multiple positive biopsies and clinical extra-prostatic ex-
tension of the disease [6]. 
Our study included only cases of high-risk prostate cancer with the po-
tential for quickly developing bone metastases due to the cancer’s aggres-
sive biological nature.
Most patients with elevated PSA levels are given anti-ADT. Anti-hor-
mone therapy may delay progression, but it is not curative for those with
rising PSA levels after definitive treatment [17]. There is no consensus on
when to start or add bisphosphonates on these patients, but adding bis-
phosphonates for early therapy is an emerging trend. Previous reports
have shown that zoledronic acid has the greatest effect in delaying skele-
tal-related events, and so this puts in perspective the early use of bispho-
sphonates  to  prevent  demineralization  and  pain  [18].  Our  study
concentrated on high-risk cases that began IV clodronate treatment tri-
monthly with the intent to reduce the secondary untoward effects of dem-
ineralization. After a minimum of 50 months of follow-up, a clear
statistical difference could be observed in favor of the regular use of bis-
phosphonates, regardless of the type of therapy administered for localized
prostate cancer (Fig. 1).
Some pharmaceutical companies recommend monthly or three-week
scheduled infusions when pain is present and three-month or an annual
dose when the protective effect on demineralization is the goal; however,
there are an insufficient number of reports that have focused on the time
of initiation and treatment duration as well as the ideal treatment schedule
[19,20]. The tri-monthly schedule was empirically chosen for our patients
due to the absence of pain and the high adherence rate. This high adher-
ence rate was achieved because clodronate was administered intra-
venously, which narrowed the patient's choices or self-administration
options observed for oral administration. Our intravenous treatment rein-
forced our previous experience that there is a high rate of patients aban-
doning treatment with the oral route of drug administration [21] due to
the necessity of a regular intake of oral bisphosphonates, and the patients
with oral administration showed poor adherence/persistence in taking the
drugs for this slowly-progressing disease. Furthermore, prevention of bone
metastasis with oral clodronate in an ongoing trial (MRC PR04) revealed
no adjuvant benefit compared to a placebo [22], which encouraged us to
study the IV route.
Our study supports the notion that bisphosphonates prevent bone
metastasis, as has been previously demonstrated with breast cancer
[23,24]. Thus, the early use of bisphosphonates for the prevention of bone
metastasis is logical, yet clodronate is a bisphosphonate that does not con-
tain nitrogen. Nitrogen-containing bisphosphonates target the mevalonate
pathway, whereas clodronate promotes osteoclast apoptosis and ultimately
impairment of bone resorption.
Our long-term follow-up may be considered rather short with regard
to prostate cancer analysis, but we achieved statistically-significant results.
Our findings demonstrate the strong impact of bisphosphonate therapy in
a high-risk patient group for recurrence of treated prostate cancer, and the
bisphosphonate therapy delayed the time to the first bone metastasis seven-
fold as compared to those patients who did not receive bisphosphonates.
This is the first report showing the adjuvant effect of bisphosphonates on
the delay of bone metastasis. 
Furthermore, an additional trial recently revealed an extended survival
benefit for those patients with metastases at the beginning of the trial when
using oral clodronate compared to those patients who did not use the drug
[25]. However, in that trial, the patients were treated with radiotherapy or
ADT and they had a less favorable clinical picture, whereas the patients
in our study were homogeneous, and we concentrated on only organ-con-
fined high-risk patients treated with an intention to cure.
The high heterogeneity of the prostate cancer spectrum is a limitation
of enrollment for trials and it is also a confounding factor. Few of our cases
had a bone biopsy that confirmed metastasis, and this might be criticized,
but the sequential comparison of routine bone scans and scintigraphy
played a crucial role in determining the metastatic nature of the bone scan
lesions.
Our attempt to enroll only patients with high-risk cancers enhanced our
analysis of the metastasis process.
C onclusion
The addition of trimestral IV bisphosphonate infusion to the regular
therapy for preventing bone demineralization in high risk cancer patients
demonstrated a protective effect of delaying the bone metastasis process
by 7 times compared to that of the patients who did not receive it. 
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